<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11180569</article-id><article-id pub-id-type="pmcid-ver">PMC11180569.319</article-id><article-id pub-id-type="pmcaid">11180569</article-id><article-id pub-id-type="pmcaiid">11180569</article-id><article-id pub-id-type="manuscript-id">NIHMS1995702</article-id><article-id pub-id-type="pmid">38670531</article-id><article-id pub-id-type="doi">10.1016/j.josat.2024.209383</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1995702</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1995702</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Saunders</surname><given-names initials="EC">Elizabeth C.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Budney</surname><given-names initials="AJ">Alan J.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cavazos-Rehg</surname><given-names initials="P">Patricia</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Scherer</surname><given-names initials="E">Emily</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bell</surname><given-names initials="K">Kathleen</given-names></name><degrees>MS</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>John</surname><given-names initials="D">Deepak</given-names></name><degrees>BA</degrees><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marsch</surname><given-names initials="LA">Lisa A.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire, USA.</aff><aff id="A2"><label>b</label>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</aff><aff id="A3"><label>c</label>New York Medical College</aff><author-notes><corresp id="CR1"><bold>Correspondence should be addressed to:</bold> Elizabeth C. Saunders, 46 Centerra Parkway, Suite 301, Lebanon, New Hampshire, 03766 USA. <email>elizabeth.c.saunders@dartmouth.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P43"><bold>Declarations of interest:</bold> None</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P46">Declaration of interests</p><p id="P47">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>24</day><month>4</month><year>2024</year></pub-date><volume>163</volume><issue-id pub-id-type="pmc-issue-id">464965</issue-id><fpage>209383</fpage><lpage>209383</lpage><pub-history><event event-type="nihms-submitted"><date><day>02</day><month>06</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 17:25:15.950"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1995702.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">Over the past decade, treatment for opioid use disorder has expanded to include long-acting injectable and implantable formulations of medication for opioid use disorder (MOUD), and integrated treatment models systematically addressing both behavioral and physical health. Patient preference for these treatment options has been underexplored. Gathering data on OUD treatment preferences is critical to guide the development of patient-centered treatment for OUD. This cross-sectional study assessed preferences for long-acting MOUD and integrated treatment using an online survey.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">An online Qualtrics survey assessed preferences for MOUD formulation and integrated treatment models. The study recruited participants (n=851) in October and November 2019 through advertisements or posts on Facebook, Google AdWords, Reddit, and Amazon Mechanical Turk (mTurk). Eligible participants scored a two or higher on the opioid pain reliever or heroin scales of the Tobacco, Alcohol Prescription Medication and other Substance Use (TAPS) Tool. Structured survey items obtained patient preference for MOUD formulation and treatment model. Using stated preference methods, the study assessed preference via comparison of preferred options for MOUD and treatment model.</p></sec><sec id="S3"><title>Results:</title><p id="P3">In the past year, 824 (96.8%) participants reported non-prescribed use of opioid pain relievers (mean TAPS score=2.72, SD=0.46) and 552 (64.9%) reported heroin or fentanyl use (mean TAPS score=2.73, SD=0.51). Seventy-four percent of participants (n=631) reported currently or previously receiving OUD treatment, with 407 (48.4%) receiving MOUD. When asked about preferences for type of MOUD formulation, 452 (53.1%) preferred a daily oral formulation, 115 (13.5%) preferred an implant, 114 (13.4%) preferred a monthly injection and 95 (11.2%) preferred a weekly injection. Approximately 8.8% (n=75) would not consider MOUD regardless of formulation. The majority of participants (65.2%, n=555) preferred receiving treatment in a specialized substance use treatment program distinct from their medical care, compared with receiving care in an integrated model (n=296, 34.8%).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">Though most participants expressed willingness to try long-acting MOUD formulations, the majority preferred short-acting formulations. Likewise, the majority preferred non-integrated treatment in specialty substance use settings. Reasons for these preferences provide insight on developing effective educational tools for patients and suggesting targets for intervention to develop a more acceptable treatment system.</p></sec></abstract><kwd-group><kwd>patient preference</kwd><kwd>medication for opioid use disorder</kwd><kwd>treatment models</kwd><kwd>integrated treatment</kwd><kwd>web-based recruitment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>